PAM
VNDA icon

Princeton Alpha Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Princeton Alpha Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,440
Closed -$218K – 953
2016
Q2 		$218K Buy
+19,440
New +$188K 0.04% 644

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Princeton Alpha Management's VNDA Position: Q3 2016 in Review

Princeton Alpha Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2016, closing a stake of 19,440 shares — an estimated $218K sold.

Princeton Alpha Management first reported a position in VNDA in Q2 2016 and held it in 1 quarter. The position peaked at $218K in Q2 2016. 140 funds tracked by Wall St. Rank hold VNDA as of Q3 2016.

  • Princeton Alpha Management reported no remaining Vanda Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Princeton Alpha Management sold 19,440 Vanda Pharmaceuticals shares in Q3 2016, an estimated $218K.
  • Princeton Alpha Management first reported a position in Vanda Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Vanda Pharmaceuticals position peaked at $218K in Q2 2016.
  • 140 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2016.

Based on Princeton Alpha Management's 13F filing for Q3 2016, filed 10 Nov 2016.